– MT-303 programs immune cells directly in patients; the first time an in vivo CAR has been evaluated clinically in HCC – CAMBRIDGE, Mass., November 8, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, announced today an oral presentation at the Society for Immunotherapy in Cancer […]

– MT-303 is Myeloid’s second clinical in vivo mRNA CAR program; it incorporates proprietary next-generation mRNA innovations – – MT-303 programs immune cells directly in patients; the first time an in vivo CAR has been evaluated in HCC – CAMBRIDGE, Mass., July 30, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage immunology company advancing RNA […]